Ipamorelin is strictly for laboratory research and is commonly employed in the following investigational areas:

Bone Health and Mineralization

Ipamorelin is extensively studied for its impact on skeletal integrity. In adult female rat models, administration of Ipamorelin has been shown to increase bone mineral content (BMC). Furthermore, it is used to investigate countermeasures against catabolic states; research indicates it can counteract the decrease in bone formation induced by glucocorticoid treatment.

Gastric Motility and Ileus

Functioning as a ghrelin mimetic, Ipamorelin is used to study gastrointestinal contractility. In rodent models of postoperative ileus, researchers utilize this peptide to assess its efficacy in accelerating gastric emptying and ameliorating gastric dysmotility.

Body Composition and Metabolism

Researchers employ Ipamorelin to explore the management of body composition, particularly in the context of hypogonadism where muscle retention and adipose tissue regulation are primary endpoints.

Pathway / Mechanistic Context

The primary mechanism of action for Ipamorelin in research settings is the selective agonism of the GHS-R1a.

• Receptor Activation: Ipamorelin binds to the GHS-R1a in the pituitary, mimicking ghrelin.
• GH Release: This binding triggers a signaling cascade that results in the release of stored Growth Hormone.
• Selectivity Profile: Unlike other GHS compounds, Ipamorelin does not activate the pathways responsible for releasing ACTH or cortisol, thereby avoiding the “stress response” often seen with less selective secretagogues.

Preclinical Research Summary

Published preclinical literature documents investigations of Ipamorelin across multiple experimental models:

• Bone Density: Studies in rats demonstrate that Ipamorelin treatment significantly increases bone mineral content (BMC) and increases the linearized bone growth rate.
• Glucocorticoid Counteraction: Research utilizing corticosteroid-treated rats indicates that Ipamorelin can fully reverse the steroid-induced reduction in bone formation rates.
• Gastrointestinal Recovery: In models of postoperative ileus, Ipamorelin administration was observed to reverse the delay in gastric emptying, suggesting a potent prokinetic effect mediated by GHS receptors.

Form & Analytical Testing

This material is produced via robust solid-phase peptide synthesis and supplied as a lyophilized (freeze-dried) powder.

• Lyophilization: Removes water content under vacuum to maintain peptide integrity and extend shelf-life.
• Identity Verification: Each lot undergoes Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the ≥99% purity standard required for reproducible research data.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Oxford University Press (OUP). https://doi.org/10.1530/eje.0.1390552
• Svensson, J., et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Bioscientifica. https://doi.org/10.1677/joe.0.1650569
• Andersen, N. B., et al. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Elsevier BV. https://doi.org/10.1054/ghir.2001.0239
• Kim, S.-H., & Park, M.-J. (2017). Effects of growth hormone on glucose metabolism and insulin resistance in human. Korean Society of Pediatric Endocrinology. https://doi.org/10.6065/apem.2017.22.3.145
• Sinha, D. K., et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. AME Publishing Company. https://doi.org/10.21037/tau.2019.11.30
• Greenwood-Van Meerveld, B., et al. (2012). Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Informa UK Limited. https://doi.org/10.2147/jep.s35396

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.